Inovio pharmaceuticals stock.
Apr 4, 2023 · Shares of Inovio Pharmaceuticals ( INO -2.12%) were down more than 10% on Tuesday afternoon, falling to a 52-week low of $0.07036 a share at one point. The biotechnology company specializes in ...
Inovio Pharmaceuticals. Market Cap. $137M. Today's Change. (-3.25%) -$0.02. Current Price. $0.51. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium ...WebInovio Pharmaceuticals (INO 2.77%) Q2 2023 Earnings Call Aug 09, 2023, 4:30 p.m. ET. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Good day, and ...INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). The …Shares of Inovio Pharmaceuticals ( INO -2.12%) were down more than 10% on Tuesday afternoon, falling to a 52-week low of $0.07036 a share at one point. The biotechnology company specializes in ...
As of September 30, 2022, INOVIO had 249.5 million common shares outstanding and 268.7 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt. INOVIO reported ...Inovio Pharmaceuticals reported quarterly losses of 15 cents per share which beat the analyst consensus estimate of a loss of 30 cents. The company also reported quarterly sales of $9.15 million ...What Happened : Inovio Pharmaceuticals reported quarterly losses of 22 cents per share which missed the analyst consensus estimate of a loss of 17 cents. The company also reported quarterly sales ...Web
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2023. Find the latest Inovio Pharmaceuticals ...Inovio Pharmaceuticals 's revenue in 2023 is $854,026. On average, 3 Wall Street analysts forecast INO's revenue for 2023 to be $227,397,691, with the lowest INO revenue forecast at $191,090,497, and the highest INO revenue forecast at $272,986,424.Web
Inovio Pharmaceuticals, Inc. Common Stock (INO) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.PLYMOUTH MEETING - INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that first quarter 2023 financial results will be released after the market close on May 10, 2023.. …Data delayed at least 15 minutes, as of Nov 17 2023 07:01 GMT. More ▽. Find ...Inovio Pharmaceuticals (INO) Company Description: Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA ...Lead Case No. 2:20-cv-01962-GJP. NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER. DERIVATIVE ACTIONS. TO: ALL RECORD HOLDERS AND BENEFICIAL OWNERS OF INOVIO PHARMACEUTICALS, INC ...Web
Inovio Pharmaceuticals (INO 4.20%) ... This leads to the biggest concern of all about Inovio. The biotech stock has skyrocketed in 2020 based on expectations of success for its COVID-19 vaccine ...
Aug 9, 2023 · Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation from European Commission in second quarter Scaling resources and headcount to align with strategic focus on INO-3107 and late-stage clinical candidates closest to market and with greatest opportunity to deliver on the promise of DNA medicines for ...
Green flag: A rich pipeline. Small-cap biotechs need promising pipeline programs to attract attention. In this department, Inovio Pharmaceuticals doesn't disappoint. The company currently boasts ...Inovio Pharmaceuticals Inc. analyst ratings, historical stock prices, ... Actuals & Estimates Inovio Pharmaceuticals Inc. Quarterly; Annual; Actual Analyst Range Consensus. 0.10 0.00-0.10-0.20 ...Analysts have been eager to weigh in on the Healthcare sector with new ratings on Actinium Pharmaceuticals (ATNM – Research Report) and Inovio Pharmaceuticals (INO – Research Report).Actinium ...WebINVESTORS. & MEDIA. Loading... INOVIO is a clinical stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases.Inovio Pharmaceuticals is easily one of the most volatile stocks on the market right now. Even relatively mild news, such as its recent Q4 results, was enough to send the stock plunging 28%.Nov 30, 2023 · Inovio Pharmaceuticals Inc INO Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation... 18 Mar 2020 ... Joseph Kim violated federal securities laws. It is being brought on behalf of all persons who acquired Inovio common stock (NASDAQ: INO) between ...
Shares of Inovio Pharmaceuticals ... Inovio's stock went on a tear during the first half of the year -- gaining as much as 860% -- mostly thanks to its efforts to develop a vaccine for COVID-19.Nov 28, 2023 · 52-week High/Low: $2.07 / $0.32. 50/200 Day Moving Average: $0.407 / $0.664. This figure corresponds to the Average Price over the previous 50/200 days. For Inovio Pharmaceuticals stocks, the 50-day moving average is the support level today. For Inovio Pharmaceuticals stocks, the 200-day moving average is the resistance level today. The stock price of Inovio Pharmaceuticals, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large 27% drop over the last ten ...Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.Inovio Pharmaceuticals, Inc., et al., No. 2:20-cv-01402-GJP (the “Action”) ... If you purchased or otherwise acquired Inovio common stock between February 14, 2020 and August 10, 2020, inclusive, you are a Class Member.Nov 30, 2023 · Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA ...
Inovio Pharmaceuticals reported quarterly losses of 15 cents per share which beat the analyst consensus estimate of a loss of 30 cents. The company also reported quarterly sales of $9.15 million ...The latest price target for Inovio Pharmaceuticals ( NASDAQ: INO) was reported by RBC Capital on Thursday, May 11, 2023. The analyst firm set a price target for 2.00 expecting INO to rise to ...
Inovio Pharmaceuticals 's revenue in 2023 is $854,026. On average, 3 Wall Street analysts forecast INO's revenue for 2023 to be $227,397,691, with the lowest INO revenue forecast at $191,090,497, and the highest INO revenue forecast at $272,986,424.WebIt seems like a long time ago that Inovio Pharmaceuticals ... Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002.WebOverview Stock Screener Earnings Calendar Sectors Nasdaq | INO U.S.: Nasdaq Inovio Pharmaceuticals Inc. Watch NEW Set a price target alert After Hours Last Updated: Nov 22, 2023 7:33 p.m.... See the company profile for Inovio Pharmaceuticals, Inc. (INO) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives ...plymouth meeting, pa., june 23, 2023 (globe newswire) - inovio (nasdaq:ino) has released the following pursuant to an order of the united states district court eastern district of pennsylvania: united states district court eastern district of pennsylvania in re inovio pharmaceuticals, inc. derivative litigation lead case no. 2:20-cv-01962-gjp notice of …Galectin Therapeutics Inc. 1.99. -0.13. -6.13%. Get Inovio Pharmaceuticals Inc (INO:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.12 Feb 2014 ... Executives and guests of Inovio Pharmaceuticals, Inc. will visit the New York Stock Exchange (NYSE) on Wednesday, Feb 12, 2014.Inovio Pharmaceuticals. Inovio Pharmaceuticals is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate ...Inovio Pharmaceuticals saw a decline in short interest in the month of October. As of October 31st, there was short interest totaling 24,940,000 shares, a decline of 3.0% from the previous total of 25,710,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are ...
Inovio Pharmaceuticals Inc. closed $1.59 below its 52-week high ($1.99), which the company reached on January 13th. The stock outperformed some of its competitors …
If You Invested $1,000 in Inovio Pharmaceuticals’s IPO, This Is How Much Money You'd Have Now. ... Right now, though, the stock looks like a risky coronavirus play at best.
Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.WebThe latest price target for Inovio Pharmaceuticals ( NASDAQ: INO) was reported by RBC Capital on Thursday, May 11, 2023. The analyst firm set a price target for 2.00 expecting INO to rise to ... 7,000,000 shares of Inovio common stock (“Settlement Stock”) that will resolve all claims in the Action (the “Settlement”). This Notice explains important rights you may have, including your possible receipt of cash from the Settlement. 1 Your legal rights will be affected whether or not you act. Please read this Notice carefully! 1.Dec 30, 2020 · Inovio Pharmaceuticals (INO-5.34%) has given different groups of investors some wildly varying stock performances this year. If you bought its shares at the beginning of 2020, your investment is ... Trial achieved primary and secondary efficacy endpoints among all evaluable subjects in the Phase 3 multi-center, randomized, double-blind, placebo-controlled trial VGX-3100 is the first DNA medicine to achieve efficacy endpoints in a Phase 3 clinical trial INOVIO also continues to partner with QIAGEN to develop a pre-treatment predictive …Web52-week High/Low: $2.07 / $0.32. 50/200 Day Moving Average: $0.407 / $0.664. This figure corresponds to the Average Price over the previous 50/200 days. For Inovio Pharmaceuticals stocks, the 50-day moving average is the support level today. For Inovio Pharmaceuticals stocks, the 200-day moving average is the resistance level today.WebINOVIO's global Phase 3 efficacy trial receives authorization to proceed from Brazil; other countries to follow INOVIO to conduct INNOVATE Phase 3 efficacy trial with partner Advaccine in areas of world in need of COVID-19 vaccines INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA …WebINO is the ticker symbol for Inovio Pharmaceuticals, Inc., a biotechnology company that develops and commercializes DNA medicines to treat and protect people from HPV-associated diseases, cancer, and infectious diseases. The web page shows its stock price, news, analysis, and performance outlook on NasdaqGS.
If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...If You Invested $1,000 in Inovio Pharmaceuticals’s IPO, This Is How Much Money You'd Have Now. ... Right now, though, the stock looks like a risky coronavirus play at best.Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA ...Instagram:https://instagram. stock.market holidaystrading computerbest day trading brokerhow to invest 5k Inovio (INO) delivered earnings and revenue surprises of -14.29% and 42.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? lizistem stock forecast 0.3950. +0.0050. +1.28%. INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer ... ai earnings report 10 Okt 2023 ... Inovio Pharmaceuticals (INO) shares rise after FDA issued positive feedback on its plans to obtain marketing nod for lead asset against a ...Feb 28, 2023 · On March 1, Inovio Pharmaceuticals will release figures for the most recent quarter. Wall Street analysts predict losses per share of $0.168. Watch Inovio Pharmaceuticals stock price in real-time ... Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading higher again on Wednesday after surging more than 40% on Tuesday after the FDA said it can use data from the completed Phase 1 ...